<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224441</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001988-75</org_study_id>
    <nct_id>NCT04224441</nct_id>
  </id_info>
  <brief_title>Repurposing Chlorpromazine in the Treatment of Glioblastoma</brief_title>
  <acronym>RACTAC</acronym>
  <official_title>Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco G Paggi, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carlo Besta Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol,
      i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and
      adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients
      carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chlorpromazine (CPZ, Largactil, Thorazine) is a potent antagonist of the dopamine receptor D2
      (DRD2) and has been effectively and safely employed for over half a century in the treatment
      of psychiatric disorders. CPZ displays a series of remarkable bio-molecular effects in cancer
      cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide
      3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy,
      inhibition of glutamate and DRD2 receptors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Addition of chlorpromazine to the standard GBM treatment during the adjuvant phase of the therapeutic protocol in un-methylated GBM patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity evaluation of the combined treatment. Subjects will be evaluated for symptoms and adverse effects according to the NCI‐CTCAE version 5.0 grading tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Effect of of adding CPZ to the standard GBM therapy, when compared with the standard therapy alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tumor response</measure>
    <time_frame>6 months</time_frame>
    <description>Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>MGMT-Unmethylated Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Standard protocol plus chlorpromazine (CPZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorpromazine Pill</intervention_name>
    <description>The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide</description>
    <arm_group_label>Standard protocol plus chlorpromazine (CPZ)</arm_group_label>
    <other_name>Temozolomide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed histologically-confirmed supra-tentorial GBM (World Health
             Organization grade IV) patients. Whenever feasible, patients will undergo maximal
             surgical resection or debulking, although patients with inoperable glioblastomas are
             also eligible.

          2. Progression-free patients after having undergone maximal safe debulking surgery when
             feasible or biopsy, and

          3. Patients undergone completed standard concomitant chemo-radiotherapy with temozolomide

          4. Patients with provision of signed and dated, written informed consent prior to any
             study specific procedures, sampling and analyses.

          5. Patients (both males and females) should employ adequate contraceptive measures which
             should be maintained during the whole duration of the trial

          6. Additional eligibility criteria include: age between 18 and 70; Karnofsky Performance
             Status (KPS) score of 70 or higher; adequate kidney, liver, bone marrow, and cardiac
             function; total serum bilirubin level and liver- function values; isocitrate
             dehydrogenase 1/2 (IDH1/2) mutational status; MGMT methylation status assessment.

        Exclusion Criteria:

        Patients should not enter the study if any of the following exclusion criteria apply:

          1. Treatment with any of the following:

               -  Any other chemotherapy, immunotherapy or anticancer agents within 4 weeks before
                  enrollment in the study.

               -  Any investigational agents or study drugs from a previous clinical study within
                  30 days before the first dose of study treatment.

               -  MGMT methylated

          2. As judged by the investigator, any evidence of severe or uncontrolled systemic
             diseases, including: uncontrolled hypertension; active bleeding diatheses; active
             hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV infection. Screening for
             chronic conditions is not required; inadequate bone marrow reserve or organ function,
             as demonstrated by laboratory parameters.

        4. Judgment by the investigator that the patient should not participate to the study if the
        patient is unlikely to comply with study procedures, restrictions and requirements.

        5. Contraindications to MRI and or magnetic resonance spectroscopy (MRS). 6. Patients not
        able to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco G Paggi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Elena Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Pace, MD</last_name>
    <phone>+39 06 52666975</phone>
    <email>andrea.pace@ifo.gov.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Giannarelli, PhD</last_name>
    <phone>+39 06 52665607</phone>
    <email>diana.giannarelli@ifo.gov.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regina Elena Cancer Institute</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pace, MD</last_name>
      <phone>+39 06 52666975</phone>
      <email>andrea.pace@ifo.gov.it</email>
    </contact>
    <contact_backup>
      <last_name>Diana Giannarelli, PhD</last_name>
      <phone>+39 06 52665607</phone>
      <email>diana.giannarelli@ifo.gov.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carlo Besta Neurological Institute</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Silvani, MD</last_name>
      <email>antonio.silvani@istituto-besta.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Lombardi, MD</last_name>
      <email>giuseppe.lombardi@iov.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cohen BM, Lipinski JF. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci. 1986 Dec 29;39(26):2571-80.</citation>
    <PMID>2879204</PMID>
  </reference>
  <reference>
    <citation>Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol. 1999 Oct 15;58(8):1229-36.</citation>
    <PMID>10487524</PMID>
  </reference>
  <reference>
    <citation>Pinheiro T, Otrocka M, Seashore-Ludlow B, Rraklli V, Holmberg J, Forsberg-Nilsson K, Simon A, Kirkham M. A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth. Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):477-483. doi: 10.1016/j.bbrc.2017.10.106. Epub 2017 Oct 21.</citation>
    <PMID>29066348</PMID>
  </reference>
  <reference>
    <citation>Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, Elliott P, Borisy AA, Keith CT. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 2007 Dec 1;67(23):11359-67.</citation>
    <PMID>18056463</PMID>
  </reference>
  <reference>
    <citation>Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, Lee YH. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013 Sep;34(9):2080-9. doi: 10.1093/carcin/bgt169. Epub 2013 May 20.</citation>
    <PMID>23689352</PMID>
  </reference>
  <reference>
    <citation>Barygin OI, Nagaeva EI, Tikhonov DB, Belinskaya DA, Vanchakova NP, Shestakova NN. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics. Brain Res. 2017 Apr 1;1660:58-66. doi: 10.1016/j.brainres.2017.01.028. Epub 2017 Feb 3.</citation>
    <PMID>28167075</PMID>
  </reference>
  <reference>
    <citation>Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC, Monje M. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019 Sep;573(7775):539-545. doi: 10.1038/s41586-019-1563-y. Epub 2019 Sep 18.</citation>
    <PMID>31534222</PMID>
  </reference>
  <reference>
    <citation>Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgöz AA, Herrmannsdörfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hänggi D, Liu HK, Wick W, Winkler F, Kuner T. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019 Sep;573(7775):532-538. doi: 10.1038/s41586-019-1564-x. Epub 2019 Sep 18.</citation>
    <PMID>31534219</PMID>
  </reference>
  <reference>
    <citation>Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, McCabe BD, Galván JA, Robinson HPC, Zlobec I, Ciriello G, Hanahan D. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019 Sep;573(7775):526-531. doi: 10.1038/s41586-019-1576-6. Epub 2019 Sep 18.</citation>
    <PMID>31534217</PMID>
  </reference>
  <reference>
    <citation>Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, Hong Park C, Saathoff MR, Warnke L, Xiao T, Lesniak MS, James CD, Meltzer H, Tryba AK, Ahmed AU. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. J Neurosci. 2019 Mar 13;39(11):1982-1993. doi: 10.1523/JNEUROSCI.1589-18.2018. Epub 2019 Jan 16.</citation>
    <PMID>30651332</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Marco G Paggi, MD, PhD</investigator_full_name>
    <investigator_title>Medical Doctor, Clinical Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>drug repurposing</keyword>
  <keyword>antipsychotic drugs</keyword>
  <keyword>glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Chlorpromazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified patient data describing primary and secondary outcomes will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after 6 months after study completion</ipd_time_frame>
    <ipd_access_criteria>Upon request. A valid Uniform Resource Locator (URL) will be reported</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

